NYSE$YCBD

cbdMD Inc · Q2 2026 earnings

Q2 2026 earnings · · After market close · Investor relations

Briefing

cbdMD Inc reported 19% revenue growth in Q2 2026 driven by the Bluebird acquisition and wholesale channel expansion.

cbdMD Inc achieved net sales of $5.64 million for the three months ended March 31, 2026, up from $4.75 million in the prior year quarter. The company posted a net loss of $798 thousand and an operating loss of $801 thousand, with gross margin declining to 57.7%. Management highlighted ongoing regulatory uncertainty around hemp-derived THC products and progress integrating the Bluebird acquisition.

  • Q2 revenue rose 19% year-over-year to $5.64 million, with direct-to-consumer sales at 67% of total.
  • Gross profit margin compressed to 57.7% due to higher wholesale mix and regulatory-related repacking costs.
  • Bluebird acquisition added revenue and customer base but contributed approximately $75 thousand in integration costs during the quarter.
  • Adjusted EBITDA loss widened slightly to $221 thousand amid increased marketing and professional service expenses.

Headline financials

Total Revenue

$5.64M

Previous: $4.75M+18.8%
EPS (adj)

-$0.08

Previous: -$1.90+95.8%
Adjusted EBITDA

-$221K

No prior period
Gross profit margin

57.7%

Previous: 62.0%-6.9%
Operating expenses

$4.06M

Previous: $3.45M+17.8%
Capital Expenditures

-$171K

Previous: -$180K+5.2%
Free Cash Flow

-$1.71M

Previous: -$661K-158.2%
Net Income

-$798K

Previous: -$481K-66.0%
Operating Income

-$801K

Previous: -$486K-64.8%
Gross Profit

$3.26M

Previous: $2.96M+10.1%
Cash & Equivalents

$2.64M

Previous: $1.77M+49.5%
Total Assets

$12.3M

Previous: $10.9M+12.0%

Revenue & EPS history

cbdMD · Revenue · Quarterly

$5.64M

Q2 2026+18.8%vs Q2 2025
Beat estimate in 2 of 14 quarters(14%)
ActualEstimate

Revenue by segment

cbdMD · $3.8M total across 1 segment · Q2 2026

  • E-commerce sales
    $3.8M

Forward guidance

Management continues to monitor evolving federal and state hemp regulations while pursuing Medicare reimbursement opportunities and additional acquisitions.

Tailwinds

  • Bluebird acquisition expected to contribute over $500 thousand quarterly revenue at healthy margins.
  • Participation in CMS Medicare reimbursement program launched April 1, 2026.
  • ELOC facility provides access to up to $20 million in additional capital.

Headwinds

  • Potential material adverse impact from H.R. 5371 THC limits effective November 2026.
  • Ongoing state-level regulatory changes increasing compliance costs.
  • Continued net losses and accumulated deficit of $180.6 million raise going concern considerations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2026

Historical avgQ2 2026

-0.5%

Avg return

Earnings day

-3.1%

Avg return

5 days after

-10.8%

Avg return

30 days after

42%

15 / 36 earnings

Positive

+70.1%

Q2 2020

Best reaction

-22.4%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+0.0%+5.3%-38.9%
Q3 2025-11.1%-22.4%-20.0%
Q2 2026-4.0%-8.2%-13.2%
Q2 2025-4.0%-8.2%-13.2%
Q1 2025-15.1%-24.6%-52.6%
Q4 2024-15.7%-22.1%+14.4%
Q3 2024+3.7%+2.1%+7.6%
Q2 2024+0.0%+1.0%-8.6%
Q1 2024-12.3%-5.5%-0.7%
Q4 2023+7.9%+6.4%+17.7%
Q3 2023+0.7%-5.6%-9.8%
Q2 2023-6.9%-6.0%-21.6%
Q1 2023-5.8%+1.8%-28.1%
Q4 2022-22.4%-29.9%-8.6%
Q3 2022-5.9%-11.6%-48.4%
Q2 2022+8.4%+28.6%-31.7%
Q1 2022-19.5%-16.3%-14.0%
Q4 2021+3.5%+0.9%-7.1%
Q3 2021-5.0%-7.8%+3.7%
Q2 2021-21.8%-17.4%-0.3%
Q1 2021+15.2%-9.2%-19.4%
Q4 2020+15.1%+6.5%+6.5%
Q3 2020+8.1%+10.2%-27.6%
Q2 2020+70.1%+71.1%+54.6%
Q1 2020+2.6%+0.0%-40.9%
Q4 2019-0.7%-1.4%-59.7%
Q3 2019-9.4%-11.6%-11.4%
Q2 2019-3.1%+0.6%-2.0%
Q1 2019+1.8%+6.5%-9.7%
Q4 2018-12.4%-21.1%+7.2%
Q3 2017+14.4%+1.4%+13.0%
Q3 2018+14.4%+1.4%+13.0%
Q2 2017-1.2%-10.2%-22.3%
Q2 2018-1.2%-10.2%-22.3%
Q1 2018-7.7%-10.1%-14.3%
Q4 2017+2.9%+5.3%+18.6%
Q1 2017
Q4 2016
Q3 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro